[go: up one dir, main page]

AU2001278117A1 - Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen - Google Patents

Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Info

Publication number
AU2001278117A1
AU2001278117A1 AU2001278117A AU7811701A AU2001278117A1 AU 2001278117 A1 AU2001278117 A1 AU 2001278117A1 AU 2001278117 A AU2001278117 A AU 2001278117A AU 7811701 A AU7811701 A AU 7811701A AU 2001278117 A1 AU2001278117 A1 AU 2001278117A1
Authority
AU
Australia
Prior art keywords
antigen
endoplasmic reticulum
chaperone polypeptide
reticulum chaperone
molecular vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278117A
Inventor
Chien-Fu Hung
Tzyy-Choou Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2001278117A1 publication Critical patent/AU2001278117A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2001278117A 2000-08-03 2001-08-02 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen Abandoned AU2001278117A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22290200P 2000-08-03 2000-08-03
US60/222,902 2000-08-03
PCT/US2001/024134 WO2002012281A2 (en) 2000-08-03 2001-08-02 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Publications (1)

Publication Number Publication Date
AU2001278117A1 true AU2001278117A1 (en) 2002-02-18

Family

ID=22834209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278117A Abandoned AU2001278117A1 (en) 2000-08-03 2001-08-02 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Country Status (8)

Country Link
US (3) US7342002B2 (en)
EP (1) EP1363938B1 (en)
JP (2) JP5087201B2 (en)
AU (1) AU2001278117A1 (en)
CA (1) CA2417214C (en)
DK (1) DK1363938T3 (en)
ES (1) ES2454640T3 (en)
WO (1) WO2002012281A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7318928B2 (en) * 2000-08-01 2008-01-15 The Johns Hopkins University Molecular vaccine linking intercellular spreading protein to an antigen
DK1363938T3 (en) 2000-08-03 2014-03-24 Univ Johns Hopkins Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen
WO2002061113A2 (en) 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
AU2004230803A1 (en) * 2003-04-18 2004-10-28 Chiba, Joe Immunogen, composition for immunological use and process for producing antibody using the same
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
WO2005081716A2 (en) * 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
WO2006041157A1 (en) 2004-10-15 2006-04-20 Sekisui Chemical Co., Ltd. Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
JP2008528004A (en) * 2005-01-26 2008-07-31 ザ ジョンズ ホプキンス ユニバーシティー Anticancer DNA vaccine using plasmid encoding mutant oncoprotein antigen and calreticulin
CN101378781B (en) * 2005-08-03 2013-08-07 美国弗劳恩霍夫股份有限公司 Compositions and methods for production of immunoglobulins
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
EP1984388B1 (en) * 2006-02-13 2016-07-06 iBio, Inc. Hpv antigens, vaccine compositions, and related methods
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
WO2008046251A1 (en) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Fusion proteins containing n domain of human calreticulin and human papillomavirus type 16 e6 or e7 and uses thereof
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
WO2008119024A1 (en) * 2007-03-27 2008-10-02 University Of Florida Research Foundation Inc. Modified antigen presenting cells and methods of use
WO2009009759A2 (en) * 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009095796A2 (en) * 2008-01-28 2009-08-06 The University Of British Columbia Tapasin augmentation for enhanced immune response
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
CA2736498C (en) * 2008-09-11 2017-05-23 Calretex, Llc Compositions and methods for purifying calreticulin
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US10487332B2 (en) * 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
EP2678031A4 (en) * 2011-02-23 2015-09-02 Univ Miami GP96-IG-VIS / COMBINED HIV OF CELL ORIGIN, RECOMBINANT GP120 PROTEIN VACCINATION FOR SCREEN PROTECTION / HIV
RS62497B1 (en) * 2011-05-24 2021-11-30 BioNTech SE Individualized vaccines for cancer
EP2752112B1 (en) * 2011-09-02 2016-04-27 Kaneka Corporation Transgenic bird expressing foreign gene using endoplasmic reticulum chaperone promoter
WO2013093629A2 (en) * 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
US9993534B2 (en) * 2013-03-12 2018-06-12 Wisconsin Alumni Research Foundation Method of treating fungal infection
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20170252417A1 (en) * 2016-03-07 2017-09-07 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7722629B2 (en) 2017-07-04 2025-08-13 キュアバック エスイー Novel nucleic acid molecules
CN109182339A (en) * 2018-09-06 2019-01-11 青岛农业大学 A kind of flat Rockfish calprotectin gene of Xu Shi and application
CR20220220A (en) 2019-11-18 2022-09-20 Janssen Biotech Inc VACCINES BASED ON CALR AND JAK2 MUTANTS AND THEIR USES

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
US4898730A (en) * 1987-03-13 1990-02-06 The University Of British Columbia Method to stimulate the immune response to specific antigens
US5582831A (en) * 1991-11-26 1996-12-10 Yeda Research And Development Co., Ltd. Anti-tumor vaccines
CA1338778C (en) 1988-06-15 1996-12-10 Richard A. Young Stress proteins and uses therefor
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
DE3907721A1 (en) * 1989-03-10 1990-09-20 Behringwerke Ag IMMUNOGENIC REGIONS ON THE E7 PROTEIN OF THE HUMAN PAPILLOMVIERUS TYPE 16
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
WO1992005248A1 (en) 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
ES2193133T3 (en) * 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh USE OF PEPTIDES DERIVED FROM THE E6 AND E7 GENES OF HPV-16 FOR PURPOSES.
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
IL106760A (en) 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5997869A (en) * 1993-03-15 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
US5426097A (en) * 1993-04-06 1995-06-20 The Trustees Of Columbia University In The City Of New York Calreticulin: a novel antithrombotic agent
EP0700445B1 (en) 1993-06-04 2002-01-23 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5591716A (en) * 1993-11-19 1997-01-07 New York University Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins
EP0659438A1 (en) 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
US5854202A (en) 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
AU5512096A (en) 1995-05-17 1996-11-29 University Of Alberta Method of inhibiting restenosis using calreticulin
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
EP0840622A4 (en) 1995-07-21 2003-01-02 Aventis Pharma Inc Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
JP4163253B2 (en) 1995-08-18 2008-10-08 スローン−ケッタリング インスティチュート フォー キャンサー リサーチ Heat shock protein-based vaccines and immunotherapy
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
DE19534348C2 (en) 1995-09-15 1997-07-10 Wieland Heinrich Prof Dr Med Method for the determination of autoimmune phenomena
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
EP0921816A4 (en) * 1996-03-28 2004-09-22 Whitehead Biomedical Inst OPSONIN-ENHANCED CELLS, AND METHOD FOR MODULATING AN IMMUNE RESPONSE TO AN ANTIGEN
CA2252675A1 (en) 1996-04-26 1997-11-06 Rijksuniversiteit Te Leiden Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
CA2265935C (en) * 1996-09-20 2006-09-05 The University Of New Mexico Heat shock protein complexes
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
AU736318B2 (en) 1996-11-26 2001-07-26 Nventa Biopharmaceuticals Corporation Immune responses using compositions containing stress proteins
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
CA2287198A1 (en) 1997-04-23 1998-10-29 Shriners Hospital For Children Calreticulin-deficient cells
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
CN1680451A (en) 1997-08-05 2005-10-12 斯特思吉生物技术公司 Immune responses against HPV antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
AU3910097A (en) 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ATE518956T1 (en) 1998-05-13 2011-08-15 Epimmune Inc EXPRESSION VECTORS FOR STIMULATING AN IMMUNE RESPONSE AND METHOD FOR USE THEREOF
KR100682666B1 (en) 1998-06-17 2007-02-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 Antiangiogenic Proteins and How to Use Them
EP1108035B1 (en) * 1998-09-04 2007-08-08 Sanofi Pasteur Limited Treatment of cervical cancer
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
US6734173B1 (en) * 1999-10-20 2004-05-11 Johns Hopkins University HSP DNA vaccines
CN1411512A (en) 1999-10-20 2003-04-16 约翰霍普金斯大学医学院 Chimeric immunogenic compositions and nucleic acids encoding the same
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US20010034042A1 (en) * 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
US6967075B2 (en) * 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
ES2263637T3 (en) 2000-06-26 2006-12-16 Stressgen Biotechnologies Corporation HPV-E7 FOR THE TREATMENT OF HUMAN PAPILOMAVIRUS.
US7318928B2 (en) * 2000-08-01 2008-01-15 The Johns Hopkins University Molecular vaccine linking intercellular spreading protein to an antigen
DK1363938T3 (en) * 2000-08-03 2014-03-24 Univ Johns Hopkins Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen
JP3930243B2 (en) * 2000-11-06 2007-06-13 本田技研工業株式会社 Magnet pump
HU230458B1 (en) * 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Rna interference mediating small rna molecules
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2002061113A2 (en) 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2002074920A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
US20030144221A1 (en) 2001-07-17 2003-07-31 Isis Pharmaceuticals Inc. Antisense modulation of BCL2-associated X protein expression
EP1417353A4 (en) * 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS FOR PREVANCER AND CANCER GROWTH PHENOMENA ASSOCIATED WITH HUMAN PAPILLOMAVIRUS, INCLUDING INTRA-EPITHELIAL CERVIC NEOPLASIA (CIN)
US20060040262A1 (en) 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
WO2003083052A2 (en) 2002-03-25 2003-10-09 The Trustees Of Boston University Method of using anti-apoptotic factors in gene expression
MXPA05003395A (en) 2002-10-03 2005-06-22 Wyeth Corp Human papillomavirus polypeptides and immunogenic compositions.
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005081716A2 (en) 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
JP2008528004A (en) 2005-01-26 2008-07-31 ザ ジョンズ ホプキンス ユニバーシティー Anticancer DNA vaccine using plasmid encoding mutant oncoprotein antigen and calreticulin

Also Published As

Publication number Publication date
ES2454640T3 (en) 2014-04-11
CA2417214A1 (en) 2002-02-14
WO2002012281A2 (en) 2002-02-14
EP1363938A2 (en) 2003-11-26
US8007781B2 (en) 2011-08-30
US20130203961A1 (en) 2013-08-08
US20090148471A1 (en) 2009-06-11
JP2004527213A (en) 2004-09-09
JP5087201B2 (en) 2012-12-05
DK1363938T3 (en) 2014-03-24
JP2009017883A (en) 2009-01-29
US20050054820A1 (en) 2005-03-10
CA2417214C (en) 2016-06-21
WO2002012281A9 (en) 2003-03-06
US7342002B2 (en) 2008-03-11
EP1363938B1 (en) 2013-12-11
WO2002012281A3 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
AU2001278117A1 (en) Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
AU2001290520A1 (en) Intercellular transport protein linked to an antigen as a molecular vaccine
AU2002309706A1 (en) Novel meningitis conjugate vaccine
AU2001252458A1 (en) Molecular antigen arrays and vaccines
PT1801219E (en) Neisserial antigenic peptides
AU2003230795A1 (en) Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
AU2001284444A1 (en) Preparations for oral administration
AU2002365924A1 (en) Herbal immune system stimulant
AU2001284418A1 (en) Novel polypeptide
AU2001250212A1 (en) Rhamm peptide conjugates
AU2002219485A1 (en) An autologous anti-cancer vaccine
AU2001242190A1 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
AU2002232803A1 (en) Expression system for recombinant proteins
AU2003264724A1 (en) Flagellin peptides as adjuvants for vaccines
AU2000277350A1 (en) Labeled peptides, and processes and intermediates useful for their preparation
AU2001227375A1 (en) N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
AU2001241187A1 (en) Sustained release oral preparations
AU2002222139A1 (en) Hcv vaccines
AU2002334631A1 (en) Immune response associated proteins
AU6224301A (en) Novel plakoglobin interacting proteins
AU2002340092A1 (en) Immunodominant acetylcholine receptor alpha subunit peptide: mhc complexes
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2001265830A1 (en) Solubilised protein vaccines
AU2001245815A1 (en) Human immune response proteins
AU2659801A (en) Shc associated protein 140 (sap-140)